GSK signed feasibility agreements with two Flagship Pioneering platform companies—ProFound Therapeutics and Quotient Therapeutics—to mine proteomic and somatic genomic datasets for drug targets in respiratory and liver diseases. The pacts are the first company-specific deals under a broader Flagship–GSK collaboration that could yield up to 10 drug programs and more than $7 billion in potential milestones. ProFound will deploy its ProFoundry proteomics platform to prioritize proteins genetically linked to COPD and idiopathic pulmonary fibrosis and run functional validation. Quotient will apply its Somatic Genomics capabilities across respiratory and liver cohorts to identify disease-causal targets for COPD, IPF and metabolic dysfunction-associated steatohepatitis. Under the terms, Flagship platform companies can advance programs through preclinical stages; GSK retains exclusive options to move candidates into clinical development. The agreements underscore Big Pharma’s preference for outsourced platform-based discovery and the continued commercial value of multi-omic datasets for target de-risking.